Silence Therapeutics (LON:SLN) released its earnings results on Monday. The company reported GBX (13.70) (($0.18)) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of GBX (21.70) (($0.28)) by GBX 8 ($0.10), Digital Look Earnings reports.
SLN stock opened at GBX 463 ($6.05) on Tuesday. The company has a quick ratio of 3.84, a current ratio of 3.88 and a debt-to-equity ratio of 1.37. The company has a market cap of $383.49 million and a price-to-earnings ratio of -17.74. The company has a 50 day moving average of GBX 465.68 and a two-hundred day moving average of GBX 445.24. Silence Therapeutics has a 12-month low of GBX 161 ($2.10) and a 12-month high of GBX 646.50 ($8.45).
Separately, Peel Hunt reiterated a “buy” rating on shares of Silence Therapeutics in a research report on Thursday, July 16th.
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.
Featured Story: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.